Daniel P. Gold
Net Worth
Last updated:
What is Daniel P. Gold net worth?
The estimated net worth of Dr. Daniel P. Gold is at least $7,843,507 as of 25 May 2021. He owns shares worth $1,663,507 as insider and has received compensation worth at least $6,180,000 in MEI Pharma, Inc..
What is the salary of Daniel P. Gold?
Dr. Daniel P. Gold salary is $1,030,000 per year as Pres, Chief Executive Officer & Director in MEI Pharma, Inc..
How old is Daniel P. Gold?
Dr. Daniel P. Gold is 71 years old, born in 1954.
What stocks does Daniel P. Gold currently own?
As insider, Dr. Daniel P. Gold owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| MEI Pharma, Inc. (MEIP) | Pres, Chief Executive Officer & Director | 361,632 | $4.6 | $1,663,507 |
What does MEI Pharma, Inc. do?
MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex that is in Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer; and Pracinostat, an oral available histone deacetylase inhibitor, which is in Phase II clinical trial to treat patients with myelodysplastic syndrome. MEI Pharma, Inc. has a license, development, and commercialization agreement with Kyowa Kirin Company; a clinical collaboration with BeiGene, Ltd.; a license, development, manufacturing, and commercialization agreement with Helsinn Healthcare SA; and a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.
Daniel P. Gold insider trading
MEI Pharma, Inc.
MEI Pharma key executives
MEI Pharma, Inc. executives and other stock owners filed with the SEC:
- Dr. Daniel P. Gold (71) Pres, Chief Executive Officer & Director
- Dr. Richard G. Ghalie (67) Chief Medical Officer
- Dr. Robert D. Mass (71) Strategic Advisor
- Mr. David M. Urso B.A., Esq., J.D. (61) Chief Operating Officer & Gen. Counsel